Karyopharm Therapeutics (KPTI) EBIT (2016 - 2025)
Historic EBIT for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$17.8 million.
- Karyopharm Therapeutics' EBIT rose 4295.58% to -$17.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$90.7 million, marking a year-over-year increase of 2405.83%. This contributed to the annual value of -$90.7 million for FY2025, which is 2405.83% up from last year.
- Per Karyopharm Therapeutics' latest filing, its EBIT stood at -$17.8 million for Q4 2025, which was up 4295.58% from -$15.2 million recorded in Q3 2025.
- In the past 5 years, Karyopharm Therapeutics' EBIT registered a high of $47.0 million during Q4 2021, and its lowest value of -$52.4 million during Q1 2021.
- Moreover, its 5-year median value for EBIT was -$31.3 million (2023), whereas its average is -$29.0 million.
- In the last 5 years, Karyopharm Therapeutics' EBIT surged by 22669.83% in 2021 and then crashed by 17212.0% in 2022.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' EBIT stood at $47.0 million in 2021, then plummeted by 172.12% to -$33.9 million in 2022, then dropped by 11.63% to -$37.8 million in 2023, then rose by 17.26% to -$31.3 million in 2024, then surged by 42.96% to -$17.8 million in 2025.
- Its EBIT stands at -$17.8 million for Q4 2025, versus -$15.2 million for Q3 2025 and -$24.4 million for Q2 2025.